Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Sell
46
VRTX Quote, Financials, Valuation and Earnings
Last price:
$434.82
Seasonality move
:
10.6%
Day range:
$428.55 - $467.85
52-week range:
$377.85 - $519.88
Dividend yield:
0%
P/E ratio:
26.10x
P/S ratio:
10.50x
P/B ratio:
7.01x
Volume:
8M
Avg. volume:
1.8M
1-year change:
11.81%
Market cap:
$115.7B
Revenue:
$11B
EPS (TTM):
-$3.92
Analysts' Opinion
-
Consensus RatingVertex Pharmaceuticals has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 14 Buy ratings, 14 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $500.30, Vertex Pharmaceuticals has an estimated upside of 11.41% from its current price of $450.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $330.00 representing 26.67% downside risk from its current price of $450.03.
Fair Value
-
According to the consensus of 29 analysts, Vertex Pharmaceuticals has 11.41% upside to fair value with a price target of $500.30 per share.
VRTX vs. S&P 500
-
Over the past 5 trading days, Vertex Pharmaceuticals has underperformed the S&P 500 by -10.66% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vertex Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vertex Pharmaceuticals has grown year-over-year revenues for 28 quarters straight. In the most recent quarter Vertex Pharmaceuticals reported revenues of $2.8B.
Earnings Growth
-
Vertex Pharmaceuticals earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Vertex Pharmaceuticals reported earnings per share of $2.49.
Enterprise value:
109.5B
EV / Invested capital:
6.64x
Price / LTM sales:
10.50x
EV / EBIT:
438.29x
EV / Revenue:
9.86x
PEG ratio (5yr expected):
1.15x
EV / Free cash flow:
-111.96x
Price / Operating cash flow:
30.13x
Enterprise value / EBITDA:
251.55x
Gross Profit (TTM):
$9.5B
Return On Assets:
-4.43%
Net Income Margin (TTM):
-8.91%
Return On Equity:
-6.04%
Return On Invested Capital:
-6.04%
Operating Margin:
37.22%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $9.2B | $10.2B | $11.1B | $2.7B | $2.8B | |
| Gross Profit | $8.1B | $8.8B | $9.5B | $2.3B | $2.4B | |
| Operating Income | $4.5B | $4.4B | $4.2B | $1.2B | $1B | |
| EBITDA | $4.4B | $5B | -$123.3M | $1.3B | $733.4M | |
| Diluted EPS | $12.56 | $15.41 | -$3.92 | $4.21 | $2.49 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.5B | $10.4B | $13B | $13.3B | $10B | |
| Total Assets | $12.1B | $14.3B | $19B | $23.9B | $22.9B | |
| Current Liabilities | $1.9B | $2.2B | $3B | $3.8B | $3.8B | |
| Total Liabilities | $3.1B | $3.3B | $4.5B | $5.4B | $6.4B | |
| Total Equity | $9B | $10.9B | $14.4B | $18.5B | $16.5B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $4.1B | $3.5B | -$492.6M | $234.6M | $584.6M | |
| Cash From Investing | -$321.1M | -$3.1B | -$3.8B | -$886.5M | -$821.9M | |
| Cash From Financing | -$67.7M | -$562.2M | -$1.5B | -$119.8M | -$391.3M | |
| Free Cash Flow | $3.9B | $3.3B | -$978M | $118.5M | $492M | |
VRTX
Sector
Market Cap
$115.7B
$34.5M
Price % of 52-Week High
86.56%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
1.27%
-0.79%
1-Year Price Total Return
11.81%
-42.08%
Beta (5-Year)
0.511
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$494.20
200-day SMA
Sell
Level
$471.31
Bollinger Bands (100)
Sell
Level
432.22 - 499.52
Chaikin Money Flow
Buy
Level
446.8M
20-day SMA
Sell
Level
$489.61
Relative Strength Index (RSI14)
Sell
Level
32.17
ADX Line
Sell
Level
18.18
Williams %R
Neutral
Level
-73.8705
50-day SMA
Sell
Level
$491.42
MACD (12, 26)
Sell
Level
-0.22
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
231.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.5862)
Buy
CA Score
(Annual)
Level (0.9334)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-6.4575)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Stock Forecast FAQ
In the current month, VRTX has received 14 Buy ratings 14 Hold ratings, and 1 Sell ratings. The VRTX average analyst price target in the past 3 months is $500.30.
-
Where Will Vertex Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vertex Pharmaceuticals share price will rise to $500.30 per share over the next 12 months.
-
What Do Analysts Say About Vertex Pharmaceuticals?
Analysts are divided on their view about Vertex Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vertex Pharmaceuticals is a Sell and believe this share price will drop from its current level to $330.00.
-
What Is Vertex Pharmaceuticals's Price Target?
The price target for Vertex Pharmaceuticals over the next 1-year time period is forecast to be $500.30 according to 29 Wall Street analysts, 14 of them rate the stock a Buy, 1 rates the stock a Sell, and 14 analysts rate the stock a Hold.
-
Is VRTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vertex Pharmaceuticals is a Leans Bullish. 14 of 29 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of VRTX?
You can purchase shares of Vertex Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vertex Pharmaceuticals shares.
-
What Is The Vertex Pharmaceuticals Share Price Today?
Vertex Pharmaceuticals was last trading at $434.82 per share. This represents the most recent stock quote for Vertex Pharmaceuticals. Yesterday, Vertex Pharmaceuticals closed at $450.03 per share.
-
How To Buy Vertex Pharmaceuticals Stock Online?
In order to purchase Vertex Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 22.52% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is down 0% over the past day.
Buy
53
SRPT alert for May 7
Sarepta Therapeutics [SRPT] is down 21.54% over the past day.
